Iteos Therapeutics Inc

Iteos Therapeutics — Investor Presentation (January 2023)

18 slides from Iteos Therapeutics's investor presentation, Jan 9, 2023

  1. Slide 1: Better Immunotherapies to Improve the Lives of People with Cancer

    Slide 1: Better Immunotherapies to Improve the Lives of People with Cancer

    Better Immunotherapies to Improve the Lives of People with Cancer iteostherapeutics.com

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements. Any statements that are not solely statements of historical fact are forward-looking statements. Words such as “believe,” “anticipate,” “plan,” “expect,” “will,” “may,” “intend,” “prepare,” “look,” “potential,” “possib

  3. Slide 3: Better Immunotherapies to Improve the Lives of People with Cancer

    Slide 3: Better Immunotherapies to Improve the Lives of People with Cancer

    Better Immunotherapies to Improve the Lives of People with Cancer iteostherapeutics.com

  4. Slide 4: iTeos well positioned to deliver better drugs to patients

    Slide 4: iTeos well positioned to deliver better drugs to patients

    iTeos well positioned to deliver better drugs to patients 3 11 Clinical drug Clinical studies planned or ongoing $ 752 M* Cash balance to fund development into 2026 68K candidates Patients diagnosed each year in US for indications in 2023 currently in development $ 2B Partnership with unique develop

  5. Slide 5: We build better drugs for people with cancer

    Slide 5: We build better drugs for people with cancer

    We build better drugs for people with cancer EOS-448: Inupadenant & EOS-984: Anti-TIGIT optimized for Designed to fully exploit immune cell activation the adenosine pathway Expansive and unique development Leverage deep understanding of the plan with GSK adenosine pathway with a focused clinical pla

  6. Slide 6: Expansive and differentiated development pipeline expected to make significant progress over 2023

    Slide 6: Expansive and differentiated development pipeline expected to make significant progress over 2023

    Expansive and differentiated development pipeline expected to make significant progress over 2023 Discovery Preclinical Phase 1 Phase 2 Phase 3 EOS-448: IgG1 antibody targeting TIGIT + dostarlimab | 1L NSCLC PDLI high * + dostarlimab | 1L NSCLC PDL1high + dostarlimab | 1L HNSCC PDL1high/low + dostar

  7. Slide 7: EOS-448 / GSK4428859A

    Slide 7: EOS-448 / GSK4428859A

    EOS-448 / GSK4428859A iteostherapeutics.com 7

  8. Slide 8: iTeos ideally positioned entering a defining year for TIGIT

    Slide 8: iTeos ideally positioned entering a defining year for TIGIT

    iTeos ideally positioned entering a defining year for TIGIT Why Validated target in two randomized trials with broad potential. TIGIT Why Antibody optimized to activate multiple types of immune cells. EOS-448 Why $2B collaboration enabling a differentiated and expansive clinical iTeos & GSK developm

  9. Slide 9: Anti-TIGIT antibody with best-in-class properties and active Fc

    Slide 9: Anti-TIGIT antibody with best-in-class properties and active Fc

    Anti-TIGIT antibody with best-in-class properties and active Fc to induce multiple types of immune response Antibody design translates to Maximize activity by leveraging Antibody design translates reduction in immunosuppressive both ends of antibody into preclinical differentiation cells in patient

  10. Slide 10: GSK's PD-1 dostarlimab is the ideal combination partner for EOS-448

    Slide 10: GSK's PD-1 dostarlimab is the ideal combination partner for EOS-448

    GSK’s PD-1 dostarlimab is the ideal combination partner for EOS-448 Dostarlimab has proven activity in lung, rectal and endometrial cancers Dostarlimab demonstrated compelling efficacy profile in head-to-head trial compared to Pembrolizumab Dostarlimab + CT Pembrolizumab + CT PERLA Study (PFS data a

  11. Slide 11: First wave of development underway in large indications

    Slide 11: First wave of development underway in large indications

    First wave of development underway in large indications EOS-448: IgG1 antibody targeting TIGIT U.S. annual incidence Discovery Preclinical Phase 1 Phase 2 Phase 3 Relapsed Refractory + dostarlimab | 1L NSCLC PDLI high * MM 1L NSCLC + dostarlimab | 1L NSCLC PDL1high PD-L1 High 56 K + dostarlimab | 1L

  12. Slide 12: Adenosine pathway

    Slide 12: Adenosine pathway

    Adenosine pathway iteostherapeutics.com 12

  13. Slide 13: Leveraging unique understanding of adenosine pathway to realize full potential

    Slide 13: Leveraging unique understanding of adenosine pathway to realize full potential

    Leveraging unique understanding of adenosine pathway to realize full potential Why Major mechanism of immunosuppression with recent clinical Adenosine validation. Pathway Why Uniquely designed for activity in solid tumors. Inupadenant Why Deep understanding of the adenosine pathway leading to iTeos

  14. Slide 14: Best-in-Class profile: Inupadenant optimized for activity at high adenosine concentration

    Slide 14: Best-in-Class profile: Inupadenant optimized for activity at high adenosine concentration

    Best-in-Class profile: Inupadenant optimized for activity at high adenosine concentration found in tumors Very high concentrations of Insurmountable, highly selective adenosine in multiple tumor types A2AR antagonist High 400 iTeos Adenosine (μM) Arcus Potency (IC50:nM 300 Corvus AstraZeneca Novarti

  15. Slide 15: Clinical activity indicates potential of iTeos-discovered biomarker to guide patient selection

    Slide 15: Clinical activity indicates potential of iTeos-discovered biomarker to guide patient selection

    Clinical activity indicates potential of iTeos-discovered biomarker to guide patient selection RECIST-evaluable patients (N=38) Biomarker case study *Progression-Free >6 Months Ongoing partial response with inupadenant monotherapy in patient with highest biomarker level observed to date Tumor: Adeno

  16. Slide 16: Leveraging our unique knowledge of adenosine pathway with focused investment

    Slide 16: Leveraging our unique knowledge of adenosine pathway with focused investment

    Leveraging our unique knowledge of adenosine pathway with focused investment Discovery Preclinical Phase 1 Phase 2 Phase 3 Inupadenant: Small molecule targeting A2A receptor Monotherapy | High Biomarker + pembrolizumab | PD-1 Resistant Melanoma + chemotherapy | Post-IO Chemo-naïve NSCLC EOS-984: Sma

  17. Slide 17: iTeos' Mission: We Build Better Drugs

    Slide 17: iTeos' Mission: We Build Better Drugs

    iTeos’ Mission: We Build Better Drugs 2023 Outlook: • Pivotal year for TIGIT • EOS-448: Optimized active TIGIT antibody with unique development plans • Inupadenant & EOS-984: Designed to exploit the adenosine pathway iteostherapeutics.com 17

  18. Slide 18: Thank You

    Slide 18: Thank You

    Thank You iteostherapeutics.com 18

Source: SEC EDGAR · 8-K filed Jan 9, 2023

More decks from Iteos Therapeutics Inc